Racial Differences in Systemic Immune Parameters in Individuals With Lung Cancer by von Itzstein, Mitchell S., MD, Liu, Jialiang, PhD, Mu-Mosley, Hong, PhD, Fattah, Farjana, PhD, Park, Jason Y., MD, PhD, SoRelle, Jeffrey A., MD, Farrar, J. David, PhD, Gwin, Mary E., MD, Hsiehchen, David, MD, Gloria-McCutchen, Yvonne, Wakeland, Edward K., PhD, Cole, Suzanne, MD, Bhalla, Sheena, MD, Kainthla, Radhika, MD, Puzanov, Igor, MD, MSCI, Switzer, Benjamin, DO, MHSA, MS, Daniels, Gregory A., MD, PhD, Zakharia, Yousef, MD, Shaheen, Montaser, MD, Zhang, Jianjun, MD, PhD, Xie, Yang, PhD, Gerber, David E., MD

Get full text

Transgenic Expression of IL15 Retains CD123-Redirected T Cells in a Less Differentiated State Resulting in Improved Anti-AML Activity in Autologous AML PDX Models by Mu-Mosley, Hong, Ostermann, Lauren, Muftuoglu, Muharrem, Vaidya, Abishek, Bonifant, Challice L, Velasquez, Mireya Paulina, Gottschalk, Stephen, Andreeff, Michael

Get full text

Distinct autoantibody profiles across checkpoint inhibitor types and toxicities by Mu-Mosley, Hong, von Itzstein, Mitchell S., Fattah, Farjana, Liu, Jialiang, Zhu, Chengsong, Xie, Yang, Wakeland, Edward K., Park, Jason Y., Kahl, Brad S., Diefenbach, Catherine S., Gerber, David E.

Get full text

Venetoclax Enhances Anti-Leukemia Activity of CD123-Specific BiTE-Secreting T-Cells in AML by Mu-Mosley, Hong, Ostermann, Lauren B, Zhao, Ran, Bonifant, Challice L., Gottschalk, Stephen, Velasquez, Mireya Paulina, Andreeff, Michael

Get full text

Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non-Small Cell Lung Cancer by von Itzstein, Mitchell S, Burns, Timothy F, Dowell, Jonathan E, Horn, Leora, Camidge, D Ross, York, Sally J, Eaton, Keith D, Kyle, Kelly, Fattah, Farjana, Liu, Jialiang, Mu-Mosley, Hong, Gupta, Arjun, Nadeem, Urooba, Gao, Ang, Zhang, Song, Gerber, David E

Get full text

Co-Targeting Intrinsic and Extrinsic Apoptosis to Maximize Cell Death Induction in Venetoclax-Resistant AML Cells by Carter, Bing Z, Tao, Wenjing, Ostermann, Lauren B, Mu-Mosley, Hong, Mak, Po Yee, Boettcher, Steffen, Nishida, Yuki, Tao, Ran, Lang, Eric, Zhai, Yifan, Yang, Dajun, Andreeff, Michael

Get full text

FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in... by Jia, Yannan, Zhang, Weiguo, Basyal, Mahesh, Chang, Kyung Hee, Ostermann, Lauren, Burks, Jared K., Ly, Charlie, Mu-Mosley, Hong, Zhang, Qi, Han, Xin, Fogler, William E., Magnani, John L., Lesegretain, Arnaud, Zal, Anna A., Zal, Tomasz, Andreeff, Michael

Get full text

Transgenic Expression of IL15 in CD123-Specific BiTE-Secreting Engager T-Cells Results in Improved Anti-AML Activity by Mu-Mosley, Hong, Ostermann, Lauren B, Muftuoglu, Muharrem, Schober, Wendy, Patel, Nalini B, Vaidya, Abishek, Bonifant, Challice L., Gottschalk, Stephen, Velasquez, Mireya Paulina, Andreeff, Michael

Get full text

Phase 1/2 trial of XPO1 inhibitor selinexor plus docetaxel in previously treated, advanced KRAS mutant non-small cell lung cancer by von Itzstein, Mitchell S, Burns, Timothy F, Dowell, Jonathan E, Horn, Leora, Camidge, D Ross, York, Sally J, Eaton, Keith D, Kyle, Kelly, Fattah, Farjana J, Liu, Jialiang, Mu-Mosley, Hong, Gupta, Arjun, Nadeem, Urooba, Gao, Ang, Zhang, Song, Gerber, David E

Get full text

Humoral and cellular correlates of a novel immune-related adverse event and its treatment by Gonugunta, Amrit S, von Itzstein, Mitchell S, Mu-Mosley, Hong, Fattah, Farjana, Farrar, J David, Mobely, Angela, Rashdan, Sawsan, Lai, Sunny, Bhai, Salman F, Bermas, Bonnie L, Karp, David, Li, Quan-Zhen, Wakeland, Edward K, Gerber, David E

Get full text